Recursion Pharmaceuticals/$RXRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Ticker
$RXRX
Sector
Primary listing
Employees
800
Headquarters
Website
RXRX Metrics
BasicAdvanced
$2.2B
-
-
-
-
Price and volume
Market cap
$2.2B
52-week high
$12.36
52-week low
$3.79
Average daily volume
62M
Financial strength
Profitability
Management effectiveness
Valuation
Growth
What the Analysts think about RXRX
Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.
Bulls say / Bears say
Recursion's AI platform advanced a cancer drug candidate into clinical trials in only 18 months, far outpacing the 42-month industry norm and highlighting its capacity to speed drug development and potentially cut R&D expenses. (Reuters)
The company is testing a subscription model like Amazon Prime, offering employers fixed-fee access per employee to all Recursion-developed therapies. This could generate stable and recurring revenue while disrupting established pharma sales channels. (Bloomberg)
As the FDA pushes to reduce animal testing, adoption of AI-driven drug discovery is rising. Recursion’s platform supports these New Approach Methodologies, positioning it to benefit from lower costs and faster timelines compared to conventional preclinical methods. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2025.
RXRX Financial Performance
Revenues and expenses
RXRX Earnings Performance
Company profitability
RXRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals (RXRX) has a market cap of $2.2B as of November 06, 2025.
What is the P/E ratio for Recursion Pharmaceuticals stock?
The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of November 06, 2025.
Does Recursion Pharmaceuticals stock pay dividends?
No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Recursion Pharmaceuticals dividend payment date?
Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) does not currently have a Beta indicator.